Exscientia

company

About

Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.

  • 101 - 250

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$100M
Industries
Artificial Intelligence,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2012
Number Of Employee
101 - 250
Operating Status
Active

Exscientia is applying AI and big data processing to accelerate drug discovery and development.

At the forefront of small molecule drug discovery.

They are the first company to automate drug design, surpassing conventional human endeavor.

Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters.

With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay.

With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals.

Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$451M €15M
Exscientia has raised a total of $451M €15M in funding over 2 rounds. Their latest funding was raised on Jan 10, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 10, 2022 Post-IPO Equity $100M 1 Sanofi Detail
Apr 20, 2021 Series D $225M 1 Detail
Mar 4, 2021 Series C $40M 1 Detail
May 26, 2020 Series C $60M 1 Detail
Jan 7, 2019 Series B $26M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
3
Exscientia is funded by 3 investors. Sanofi and Hongyou Investment are the most recent investors.
Investor Name Lead Investor Funding Round
Sanofi Yes Post-IPO Equity
Hongyou Investment Series D
Evotec Series C